These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 18424479

  • 1. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [Abstract] [Full Text] [Related]

  • 2. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N, Filippi M, Hawkins C, 9011 study group.
    J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 20; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 5. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 20; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 6. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Miller A, Spada V, Beerkircher D, Kreitman RR.
    Mult Scler; 2008 May 20; 14(4):494-9. PubMed ID: 18208875
    [Abstract] [Full Text] [Related]

  • 7. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
    Mult Scler; 2009 Oct 20; 15(10):1183-94. PubMed ID: 19776092
    [Abstract] [Full Text] [Related]

  • 8. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
    Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T.
    J Neurol; 2008 Oct 20; 255(10):1473-8. PubMed ID: 18854910
    [Abstract] [Full Text] [Related]

  • 9. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun 20; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 10. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group.
    Neurology; 2005 Sep 13; 65(5):690-5. PubMed ID: 16157900
    [Abstract] [Full Text] [Related]

  • 11. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
    Johnson KP, Ford CC, Lisak RP, Wolinsky JS.
    Acta Neurol Scand; 2005 Jan 13; 111(1):42-7. PubMed ID: 15595937
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 13; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 13. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.
    J Neurol Sci; 2008 Mar 15; 266(1-2):25-30. PubMed ID: 17870094
    [Abstract] [Full Text] [Related]

  • 14. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 15; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow up of glatiramer acetate compassionate use in Belgium.
    Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'Hooghe MB, Deville MC, Decoo D, Sadzot B, Van Landegem W, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Tool MA.
    Acta Neurol Belg; 2005 Jun 09; 105(2):81-5. PubMed ID: 16076061
    [Abstract] [Full Text] [Related]

  • 17. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E.
    Mult Scler; 2009 Jan 09; 15(1):50-8. PubMed ID: 18922831
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
    Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, Weiss S, Shifroni G, Wolinsky JS, Filippi M, European/Canadian Glatiramer Acetate Study Group.
    Mult Scler; 2007 May 09; 13(4):502-8. PubMed ID: 17483532
    [Abstract] [Full Text] [Related]

  • 19. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
    Kohriyama T, Higaki M, Matsumoto M.
    Nihon Rinsho; 2003 Aug 09; 61(8):1381-7. PubMed ID: 12962027
    [Abstract] [Full Text] [Related]

  • 20. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.